17015054

Source:http://linkedlifedata.com/resource/pubmed/id/17015054

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0025153, umls-concept:C0332281, umls-concept:C0678951, umls-concept:C0879626, umls-concept:C1704939
pubmed:issue	4
pubmed:dateCreated	2006-10-3
pubmed:abstractText	Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372741
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/ABCB1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Antimalarials, http://linkedlifedata.com/resource/pubmed/chemical/Cysteine, http://linkedlifedata.com/resource/pubmed/chemical/Glycine, http://linkedlifedata.com/resource/pubmed/chemical/Mefloquine, http://linkedlifedata.com/resource/pubmed/chemical/Organic Anion Transporters, http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein, http://linkedlifedata.com/resource/pubmed/chemical/Threonine
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0009-9236
pubmed:author	pubmed-author:AarnoudseAlbert L H JAL, pubmed-author:DielemanJeanneJ, pubmed-author:LigthelmRobert JRJ, pubmed-author:MolokhiaMariamM, pubmed-author:OverboschDavidD, pubmed-author:StrickerBruno H ChBH, pubmed-author:van RiemsdijkMelanie MMM, pubmed-author:van SchaikRon H NRH, pubmed-author:van der HeidenIlse PIP
pubmed:issnType	Print
pubmed:volume	80
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	367-74
pubmed:meshHeading	pubmed-meshheading:17015054-Adult, pubmed-meshheading:17015054-Aged, pubmed-meshheading:17015054-Antimalarials, pubmed-meshheading:17015054-Confidence Intervals, pubmed-meshheading:17015054-Cysteine, pubmed-meshheading:17015054-European Continental Ancestry Group, pubmed-meshheading:17015054-Female, pubmed-meshheading:17015054-Gene Frequency, pubmed-meshheading:17015054-Genes, MDR, pubmed-meshheading:17015054-Glycine, pubmed-meshheading:17015054-Haplotypes, pubmed-meshheading:17015054-Humans, pubmed-meshheading:17015054-Male, pubmed-meshheading:17015054-Mefloquine, pubmed-meshheading:17015054-Mental Disorders, pubmed-meshheading:17015054-Middle Aged, pubmed-meshheading:17015054-Nervous System Diseases, pubmed-meshheading:17015054-Odds Ratio, pubmed-meshheading:17015054-Organic Anion Transporters, pubmed-meshheading:17015054-P-Glycoprotein, pubmed-meshheading:17015054-Polymorphism, Genetic, pubmed-meshheading:17015054-Reference Values, pubmed-meshheading:17015054-Threonine, pubmed-meshheading:17015054-Travel
pubmed:year	2006
pubmed:articleTitle	MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
pubmed:affiliation	Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.
pubmed:publicationType	Journal Article